icapamespib (PU-AD) / Samus Therap  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
icapamespib (PU-AD) / Samus Therap
NCT04311515: To Evaluate Safety, Tolerability and Pharmacological Effects of PU AD in Subjects With Mild AD Dementia

Terminated
2a
4
US
Tau Positron emission tomography (PET), Fluorodeoxyglucose (FDG) Positron emission tomography (PET), Cerebrospinal fluid (CSF) Biomarkers, Blood Biomarkers, Rating Scales, PU-AD, Placebo, SyrSpend
Samus Therapeutics, Inc.
Alzheimer Disease
09/20
11/22
ALS, NCT04505358: Evaluate PU-AD in Subjects With Amyotrophic Lateral Sclerosis

Withdrawn
2
0
NA
PU-AD, active, Placebo, non active
Samus Therapeutics, Inc.
Amyotrophic Lateral Sclerosis (ALS)
12/24
01/25

Download Options